Affinage

CDH3

Cadherin-3 · UniProt P22223

Length
829 aa
Mass
91.4 kDa
Annotated
2026-06-09
62 papers in source corpus 19 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CDH3 encodes P-cadherin, a calcium-dependent classical cadherin that mediates cell-cell adhesion and shapes epithelial tissue organization and motility (PMID:15833838, PMID:11544476). Loss-of-function mutations in CDH3 cause hypotrichosis with juvenile macular dystrophy, with the gene expressed in retinal pigment epithelium and hair follicles (PMID:11544476), and missense or frameshift mutations affecting conserved Ca2+-binding motifs cause EEM syndrome, consistent with a requirement for P-cadherin in hair, retinal, and limb/digit morphogenesis (PMID:15805154, PMID:12445216). At the molecular level, P-cadherin forms trans heterophilic strand-swap dimers with the desmosomal cadherin Dsg2, terminated by conserved tryptophan residues, and this interaction nucleates and is retained through desmosome assembly. In cancer, P-cadherin overexpression drives cell motility and invasion: it engages p120ctn, causes its cytoplasmic accumulation and a cadherin switch that activates the Rho GTPases Rac1 and Cdc42 (PMID:15833838), and promotes migration through Src activation and focal adhesion reorganization (PMID:28991231); in collective invasion, a Cdh3+ leader-cell subpopulation directs protrusion dynamics via local laminin production feeding integrin/focal adhesion function (PMID:36626870). CDH3 expression is controlled by an extensive transcriptional and epigenetic network, including activation by C/EBPβ, Slug/SNAI2, KLF4, and AP-1 factors Junb/Fosl2 (PMID:20385540, PMID:23405208, PMID:31182916, PMID:28991231, PMID:36468795), promoter methylation/demethylation (PMID:16115928, PMID:31621118), and chromatin reconfiguration following CDH1/E-cadherin loss that drives an E- to P-cadherin switch (PMID:37372088). P-cadherin protein stability is maintained by the deubiquitinase USP8 (PMID:40700945).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2001 High

    Established CDH3 as physiologically essential by tying loss-of-function mutations to a human disease and to expression in specific tissues, defining its developmental role.

    Evidence Homozygosity mapping and mutation analysis in consanguineous HJMD families with tissue expression analysis

    PMID:11544476

    Open questions at the time
    • Did not resolve the molecular adhesion mechanism in RPE/hair follicle
    • No structural basis for mutation effects
  2. 2002 Medium

    Linked a specific conserved-residue substitution to disease, implicating loss of calcium-dependent adhesion as the pathogenic mechanism.

    Evidence Sanger sequencing, family segregation, and residue conservation analysis of the R503H HJMD mutation

    PMID:12445216

    Open questions at the time
    • Predicted Ca2+-binding domain disruption not directly tested biochemically
    • Single residue/single family
  3. 2005 Medium

    Extended CDH3 disease causation to EEM syndrome and broadened its developmental role to limb/digit morphogenesis via mutations in Ca2+-binding and truncating regions.

    Evidence Mutation analysis (N322I missense, c.829delG frameshift) and mouse in situ hybridization of apical ectodermal ridge expression

    PMID:15805154

    Open questions at the time
    • Functional consequence of truncation not assayed
    • No rescue experiment
  4. 2005 High

    Defined a pro-motility function for P-cadherin overexpression in cancer, mechanistically connecting it to p120ctn sequestration and Rho GTPase activation.

    Evidence Stable overexpression in Panc-1 cells, blocking antibody, Rho GTPase activity assays, and p120ctn co-IP/pull-down

    PMID:15833838

    Open questions at the time
    • Direct link between p120ctn accumulation and Rac1/Cdc42 GEF activation not delineated
    • In vitro only
  5. 2005 Medium

    Identified promoter hypomethylation as an epigenetic switch driving aberrant P-cadherin expression in breast cancer.

    Evidence 5-Aza-2'-deoxycytidine treatment and methylation-specific analysis of the CDH3 5'-flanking region

    PMID:16115928

    Open questions at the time
    • Specific methylation-sensitive transcription factors not identified
    • Single cell line
  6. 2010 Medium

    Began assembling the CDH3 transcriptional regulatory network, implicating chromatin remodeling and C/EBPβ in promoter activation.

    Evidence ChIP for H3K4me2, luciferase reporter assays, and promoter activity after ICI 182,780 treatment in breast cancer cells

    PMID:20385540

    Open questions at the time
    • Mechanism linking ERα antagonism to CDH3 chromatin not fully resolved
    • Single lab
  7. 2013 Medium

    Resolved isoform specificity of C/EBPβ regulation, showing transcriptional binding by all isoforms but protein-level induction only by LIP.

    Evidence DNA-protein interaction assays, site-directed mutagenesis of binding sites, and luciferase reporters

    PMID:23405208

    Open questions at the time
    • Post-transcriptional basis of LIP-specific protein induction unexplained
    • Single cell context
  8. 2017 Medium

    Showed that the EMT repressor Slug paradoxically activates CDH3 and that P-cadherin mediates Slug-driven migration through Src and focal adhesion reorganization.

    Evidence ChIP at Pcad E-boxes, genetic rescue in Slug-depleted cells, mammosphere/3D tubulogenesis/migration assays with Src inhibition

    PMID:28991231

    Open questions at the time
    • Direct Src activation mechanism by P-cadherin not defined
    • Single lab
  9. 2019 Medium

    Added KLF4 as a direct activator and placed GSK-3β downstream of P-cadherin, while revealing a context-dependent tumor-suppressive role in HCC.

    Evidence ChIP, luciferase reporters, siRNA knockdown, and overexpression with proliferation/migration assays in HCC cells

    PMID:31182916

    Open questions at the time
    • Mechanism by which P-cadherin regulates GSK-3β unresolved
    • Opposite phenotype to other cancers unexplained
  10. 2019 Medium

    Established an lncRNA-directed methylation route for CDH3 silencing, identifying ADAMTS9-AS2/DNMT recruitment as a suppressive axis.

    Evidence RNA pull-down, RIP, ChIP, methylation-specific PCR, and knockdown/overexpression with xenografts in esophageal cancer

    PMID:31621118

    Open questions at the time
    • Specificity of DNMT targeting to CDH3 promoter not fully isolated
    • Single lab
  11. 2018 Medium

    Revealed CDH3 as a target of pathogen-directed epigenetic suppression via a parasite RNA and PRDM1-mediated H3K9 methylation.

    Evidence In vitro cryptosporidiosis model, ChIP for parasite RNA and H3K9me at the CDH3 locus, and RNA knockdown rescue

    PMID:29438669

    Open questions at the time
    • Functional consequence of CDH3 suppression for infection not established
    • Single system
  12. 2022 Medium

    Identified AP-1 factors Junb/Fosl2 as cooperative activators of Cdh3 in Sertoli cells, extending the regulatory network to a reproductive context.

    Evidence AP-1 overexpression, ChIP-qPCR, reporter assays with deletions/mutagenesis, siRNA, and ATAC-seq

    PMID:36468795

    Open questions at the time
    • Role of P-cadherin in Sertoli cell function not characterized
    • Single lab
  13. 2023 Medium

    Mechanistically connected E-cadherin loss to an E- to P-cadherin switch through chromatin reconfiguration at a CDH3-eQTL regulatory element.

    Evidence CRISPR CDH1 knockout, ATAC-seq, 4C-seq from the CDH1 promoter, and CRISPR deletion of the CDH3-eQTL in gastric cancer cells

    PMID:37372088

    Open questions at the time
    • Generalizability beyond gastric cancer untested
    • Trans-regulatory contacts not fully mapped
  14. 2023 Medium

    Defined a Cdh3+/K14+ leader-cell subpopulation that directs collective invasion through local laminin deposition and integrin/focal adhesion function.

    Evidence Single-cell sequencing, 3D live imaging of tumor organoids, computational modeling, and subpopulation functional characterization

    PMID:36626870

    Open questions at the time
    • Direct molecular role of P-cadherin in laminin production not isolated
    • Single lab
  15. 2023 Medium

    Identified miR-133A as a direct post-transcriptional repressor of CDH3 governing colorectal cancer cell survival and migration.

    Evidence Luciferase reporter, qRT-PCR, western blot, siRNA, and viability/migration/apoptosis assays

    PMID:37151391

    Open questions at the time
    • Catenin/MMP/EMT marker changes correlative
    • Single lab
  16. 2025 Medium

    Established post-translational control of P-cadherin stability by the deubiquitinase USP8, with CDH3 supporting tumor growth and restraining ferroptosis.

    Evidence Co-IP, cycloheximide chase, siRNA knockdown, xenografts, and ferroptosis markers in LUAD cells

    PMID:40700945

    Open questions at the time
    • Ubiquitin ligase opposing USP8 not identified
    • Mechanistic link to ferroptosis unresolved
  17. 2025 High

    Resolved the molecular basis of P-cadherin's role in desmosome biogenesis as trans heterophilic strand-swap dimerization with Dsg2.

    Evidence Single-molecule AFM, super-resolution/confocal imaging, β-strand hinge mutagenesis, atomistic simulations, and cell-based desmosome rescue assays (preprint)

    Open questions at the time
    • Peer review pending
    • Physiological relevance to HJMD/EEM tissues not directly tested
  18. 2025 Medium

    Placed CDH3 downstream of YAP1 and WNT5A-ROR2 signaling in basal-like prostate cancer and demonstrated its tractability as an immunotherapy/ADC target.

    Evidence GEMMs, scRNA-seq, ADC cytotoxicity, CAR T assays, and xenografts (preprint)

    PMID:41332717

    Open questions at the time
    • Direct transcriptional link from WNT/YAP1 to CDH3 promoter not fully mapped
    • Preprint, single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multilayered transcriptional, epigenetic, and post-translational controls integrate to set context-specific (tumor-promoting vs. suppressive) P-cadherin levels, and how adhesion-dependent signaling converges on Rho GTPases, Src, and GSK-3β, remains unresolved.
  • No unifying model reconciling opposite cancer phenotypes
  • Quantitative link between adhesion state and downstream GTPase/kinase signaling unmeasured
  • Structural basis of disease mutations on adhesion not directly assayed

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098631 cell adhesion mediator activity 3 GO:0008092 cytoskeletal protein binding 1
Localization
GO:0005886 plasma membrane 2
Pathway
R-HSA-1643685 Disease 3 R-HSA-1266738 Developmental Biology 2 R-HSA-1500931 Cell-Cell communication 2
Partners
CTNND1DSG2USP8
Complex memberships
desmosome

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 P-cadherin/CDH3 overexpression in pancreatic cancer cells promotes cell motility through interaction with p120ctn; P-cadherin overexpression causes cytoplasmic accumulation of p120ctn and cadherin switching, which activates Rho GTPases Rac1 and Cdc42, driving increased cell motility. A blocking antibody against P-cadherin suppressed motility in vitro. Stable overexpression in P-cadherin-deficient Panc-1 cells, blocking antibody assay, Rho GTPase activity assays, co-immunoprecipitation/pull-down for p120ctn interaction Cancer research High 15833838
2001 CDH3 (encoding P-cadherin) is expressed in retinal pigment epithelium and hair follicles; loss-of-function mutations in CDH3 cause hypotrichosis with juvenile macular dystrophy (HJMD), establishing CDH3 as required for normal hair follicle and retinal pigment epithelium function. Homozygosity mapping in consanguineous families, mutation analysis (exon 8 deletion identified in all families), expression analysis of CDH3 in relevant tissues Nature genetics High 11544476
2005 CDH3 promoter hypomethylation regulates P-cadherin overexpression in breast cancer; treatment of MCF-7/AZ cells with demethylating agent 5-Aza-2'-deoxycytidine increased P-cadherin mRNA and protein levels, and normal P-cadherin-negative breast epithelial cells showed consistent CDH3 promoter methylation. Demethylating agent (5-Aza-2'-deoxycytidine) treatment, methylation-specific analysis of CDH3 5'-flanking region, correlation of methylation status with P-cadherin expression Clinical cancer research Medium 16115928
2005 CDH3 missense mutation (N322I) in a conserved Ca2+-binding motif causes EEM syndrome, and a frameshift deletion (c.829delG) producing a truncated protein lacking intracellular, transmembrane, and EC repeats 3-5 also causes EEM syndrome. CDH3 is expressed in the apical ectodermal ridge (E10.5–E12.5) and interdigital mesenchyme in mice, establishing its role in limb/digit morphogenesis. Molecular mutation analysis, mouse in situ hybridization for Cdh3 expression pattern Journal of medical genetics Medium 15805154
2002 A missense mutation R503H in CDH3 causes HJMD; the R503H substitution affects a highly conserved residue predicted to alter a Ca2+-binding domain of P-cadherin, consistent with loss of calcium-dependent adhesion function. Sanger sequencing of entire CDH3 coding sequence, segregation analysis in family, conservation analysis of affected residue The Journal of investigative dermatology Medium 12445216
2010 ICI 182,780 (an ERα antagonist) upregulates CDH3/P-cadherin expression in breast cancer cells through chromatin remodeling at the CDH3 promoter, specifically inducing H3 lysine 4 dimethylation (active chromatin mark); the transcription factor C/EBPβ is able to upregulate CDH3 promoter activity and is co-expressed with P-cadherin in human breast carcinomas. Chromatin immunoprecipitation (ChIP) for histone marks, luciferase reporter assay, CDH3 promoter activity measurement after ICI 182,780 treatment Human molecular genetics Medium 20385540
2013 All three C/EBPβ isoforms (LAP1, LAP2, LIP) function as transcriptional regulators of the CDH3 gene in breast cancer cells, directly interacting with specific regions of the CDH3 promoter. However, transcriptional activation was only reflected at the P-cadherin protein level for the LIP isoform. DNA-protein interaction assays (EMSA/ChIP), site-directed mutation analysis of C/EBPβ binding sites, luciferase reporter assay PloS one Medium 23405208
2019 KLF4 directly binds to and transcriptionally activates the CDH3 promoter in hepatocellular carcinoma cells; CDH3/P-cadherin in turn regulates GSK-3β as a downstream effector. KLF4 knockdown reduces CDH3 expression, and CDH3 knockdown promotes HCC cell growth and migration, while CDH3 overexpression suppresses these phenotypes. Luciferase reporter assay, chromatin immunoprecipitation (ChIP), siRNA knockdown, overexpression studies with proliferation and migration assays International journal of biological sciences Medium 31182916
2017 Slug (SNAI2) transcription repressor unexpectedly binds and activates the Pcad (CDH3) promoter through E-boxes, inducing P-cadherin expression. P-cadherin mediates several Slug functions including clonal mammosphere growth, basal epithelial differentiation, cell-cell dissociation, and cell migration (rescuing Slug depletion). P-cadherin-promoted migration is associated with Src activation, focal adhesion reorganization, and cell polarization. Promoter binding assay (ChIP for Slug at Pcad E-boxes), genetic rescue experiments (Pcad re-expression in Slug-depleted cells), mammosphere assay, 3D tubulogenesis assay, migration assay with Src inhibition Oncogene Medium 28991231
2022 The AP-1 transcription factors Junb and Fosl2 cooperate to regulate Cdh3 expression in Sertoli cells by recruiting to an AP-1 regulatory element at -47 bp in the proximal Cdh3 promoter. Knockdown of Junb and/or Fosl2 by siRNA decreased Cdh3 protein levels. Overexpression of AP-1 factors, ChIP-qPCR, luciferase reporter assay with 5' promoter deletions and site-directed mutagenesis, siRNA knockdown, histone modification analysis, ATAC-seq Molecular reproduction and development Medium 36468795
2023 A Cdh3/P-cadherin-positive subpopulation of keratin 14-positive breast tumor leader cells controls leader cell protrusion dynamics and directional collective migration through local production of laminin, which is required for integrin/focal adhesion function at the leading edge. Single-cell sequencing, live imaging of primary mouse and human breast tumor organoids in 3D microfluidic system, 3D computational modeling, isolation and functional characterization of Cdh3+/K14+ subpopulation, integrin/focal adhesion readouts Developmental cell Medium 36626870
2023 CDH1/E-cadherin loss in gastric cancer cells alters CDH3 locus chromatin conformation, allowing CDH1 promoter interaction with a CDH3-eQTL regulatory element and promoting CDH3/P-cadherin expression at the plasma membrane (E- to P-cadherin switch). This switch increases cell migration and proliferation. Deletion of CDH3-eQTL reduces CDH3/CDH1 expression. CRISPR-Cas9 CDH1 knockout, ATAC-seq, 4C-seq (with CDH1 promoter viewpoint), RT-PCR, flow cytometry, CRISPR deletion of CDH3-eQTL Biology Medium 37372088
2018 During Cryptosporidium parvum infection, the parasite RNA Cdg7_FLc_1000 is delivered into host cell nuclei and causes trans-suppression of the CDH3 gene in human intestinal epithelial cells via PRDM1-mediated H3K9 methylation at the CDH3 gene locus; Cdg7_FLc_1000 knockdown attenuates this CDH3 trans-suppression. In vitro cryptosporidiosis model, ChIP for Cdg7_FLc_1000 at CDH3 promoter, knockdown of parasite RNA, H3K9 methylation ChIP, RT-PCR for CDH3 expression International journal for parasitology Medium 29438669
2019 lncRNA ADAMTS9-AS2 induces methylation of the CDH3 promoter via DNMT1/DNMT3(A/B), thereby downregulating CDH3 expression and suppressing esophageal cancer cell proliferation, invasion, and migration. These interactions were confirmed by RNA pull-down, RIP, and ChIP assays. RNA pull-down, RIP (RNA immunoprecipitation), ChIP assay, MSP (methylation-specific PCR), siRNA knockdown and overexpression experiments, in vivo xenograft Molecular carcinogenesis Medium 31621118
2025 USP8 (a deubiquitinating enzyme) interacts with CDH3/P-cadherin and maintains CDH3 protein stability by removing ubiquitin (deubiquitination). CDH3 silencing inhibited LUAD cell proliferation, migration, invasion, angiogenesis, and induced ferroptosis in vitro, as well as repressed tumor growth in vivo. Co-immunoprecipitation (CoIP), Cycloheximide (CHX) chase assay for protein stability, siRNA knockdown, xenograft tumor model, ferroptosis markers (Fe2+, MDA, lipid-ROS, GSH) Tissue & cell Medium 40700945
2025 P-cadherin (CDH3) and Desmoglein-2 (Dsg2) interact as trans heterophilic strand-swap dimers, with mutually swapped β-strands terminated by conserved Tryptophan residues. This interaction facilitates desmosome assembly: cells lacking classical cadherins or expressing strand-swap-deficient Pcad show impaired desmosome formation, which is rescued by introduction of strand-swap-competent Pcad. Heterophilic Pcad-Dsg2 dimers are retained in the desmosome throughout maturation. Single-molecule Atomic Force Microscopy, super-resolution imaging, confocal imaging, mutagenesis of β-strand hinge, atomistic simulations, cell-based desmosome assembly assays bioRxivpreprint High
2023 MiR-133A directly targets CDH3 mRNA (validated by luciferase reporter assay); CDH3 knockdown in colorectal cancer cells reduces cell viability, migration, and colony formation while increasing apoptosis, and modulates catenin, MMP, and EMT pathway markers. Luciferase reporter assay, quantitative RT-PCR, western blot, siRNA knockdown, cell viability/migration/colony formation/apoptosis assays Journal of Cancer Medium 37151391
2025 In basal-like prostate cancer, YAP1 signaling and a WNT5A-ROR2 non-canonical WNT axis drive CDH3 expression. CDH3-targeted antibody-drug conjugates induce antigen-dependent cytotoxicity of CDH3+ prostate cancer cells in vitro and suppress tumor growth in vivo. CDH3-targeted CAR T cells specifically lyse CDH3-expressing cells and cause tumor regression, especially when combined with PD-1 checkpoint blockade. Genetically engineered mouse models (GEMMs), single-cell RNA sequencing, transcriptomic analyses, ADC cytotoxicity assays, CAR T cell assays, xenograft tumor models, WNT pathway component analysis bioRxivpreprint Medium 41332717
2025 Oxidative stress upregulates CDH3 expression in lung cancer cells via OGG1 (8-oxoguanine DNA glycosidase) modulation of SP1 transcription factor binding to CDH3 promoter SP1 binding sites. ChIP-qPCR for SP1 binding at CDH3 promoter, CDH3 promoter analysis, oxidative stress induction experiments Antioxidants (Basel, Switzerland) Low 40227353
2010 CDH3/P-cadherin regulates cell migration and invasion in cholangiocarcinoma (HuCCT1) cells independently of EMT; CDH3 siRNA knockdown significantly reduced migration and invasion without affecting proliferation or EMT marker expression. siRNA knockdown, migration and invasion assays, proliferation assay, EMT biomarker expression analysis Anatomy & cell biology Low 21189991

Source papers

Stage 0 corpus · 62 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clinical cancer research : an official journal of the American Association for Cancer Research 198 16115928
2005 Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer research 148 15833838
2001 Hypotrichosis with juvenile macular dystrophy is caused by a mutation in CDH3, encoding P-cadherin. Nature genetics 139 11544476
2011 Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain. Mechanisms of ageing and development 112 21878349
1996 cdh-3, a gene encoding a member of the cadherin superfamily, functions in epithelial cell morphogenesis in Caenorhabditis elegans. Development (Cambridge, England) 89 9012534
2005 Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome). Journal of medical genetics 85 15805154
2002 Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. European journal of cancer (Oxford, England : 1990) 83 12044515
2016 Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer. Oncotarget 55 26771841
2002 A missense mutation in CDH3, encoding P-cadherin, causes hypotrichosis with juvenile macular dystrophy. The Journal of investigative dermatology 51 12445216
2019 Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation. Molecular carcinogenesis 44 31621118
2020 Sulforaphene inhibits esophageal cancer progression via suppressing SCD and CDH3 expression, and activating the GADD45B-MAP2K3-p38-p53 feedback loop. Cell death & disease 39 32873775
2017 P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring. Oncoscience 36 29142905
2007 Novel CDH3 mutations in hypotrichosis with juvenile macular dystrophy. Clinical and experimental dermatology 32 17342797
2023 A Cdh3-β-catenin-laminin signaling axis in a subset of breast tumor leader cells control leader cell polarization and directional collective migration. Developmental cell 31 36626870
2011 A product analog bound form of 3-oxoadipate-enol-lactonase (PcaD) reveals a multifunctional role for the divergent cap domain. Journal of molecular biology 28 21237173
2009 A novel splice-site mutation in the CDH3 gene in hypotrichosis with juvenile macular dystrophy. Clinical and experimental dermatology 27 19076794
2009 Demethylation of the CDH3 gene is frequently detected in advanced colorectal cancer. Anticancer research 26 19528483
2019 KLF4-Mediated CDH3 Upregulation Suppresses Human Hepatoma Cell Growth and Migration via GSK-3β Signaling. International journal of biological sciences 25 31182916
1994 Acquisition of apparent DNA slippage structures during extensive evolutionary divergence of pcaD and catD genes encoding identical catalytic activities in Acinetobacter calcoaceticus. Gene 24 8181753
2009 Frequent CDH3 demethylation in advanced gastric carcinoma. Anticancer research 23 19846933
2013 CCAAT/enhancer binding protein β (C/EBPβ) isoforms as transcriptional regulators of the pro-invasive CDH3/P-cadherin gene in human breast cancer cells. PloS one 21 23405208
2014 Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3β inhibitors. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20 25169655
2010 ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPbeta in CDH3 gene activation. Human molecular genetics 20 20385540
2020 Downregulated CDH3 decreases proliferation, migration, and invasion in thyroid cancer. American journal of translational research 18 32655830
2010 CDH3/P-Cadherin regulates migration of HuCCT1 cholangiocarcinoma cells. Anatomy & cell biology 18 21189991
2011 CDH3-Related Syndromes: Report on a New Mutation and Overview of the Genotype-Phenotype Correlations. Molecular syndromology 17 22140374
2010 A novel splice-acceptor site mutation in CDH3 gene in a consanguineous family exhibiting hypotrichosis with juvenile macular dystrophy. Archives of dermatological research 17 20140736
2017 New CDH3 mutation in the first Spanish case of hypotrichosis with juvenile macular dystrophy, a case report. BMC medical genetics 16 28061825
2017 Slug/Pcad pathway controls epithelial cell dynamics in mammary gland and breast carcinoma. Oncogene 14 28991231
2016 Hypotrichosis and juvenile macular dystrophy caused by CDH3 mutation: A candidate disease for retinal gene therapy. Scientific reports 13 27157923
2017 CDH3 gene related hypotrichosis and juvenile macular dystrophy - A case with a novel mutation. American journal of ophthalmology case reports 12 29260097
2012 In vitro assessment of choline dihydrogen phosphate (CDHP) as a vehicle for recombinant human interleukin-2 (rhIL-2). Cellular and molecular bioengineering 12 24504148
2023 Biomarkers for Premature Coronary Artery Disease (PCAD): A Case Control Study. Diagnostics (Basel, Switzerland) 10 36672997
2025 A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity. mAbs 8 39762718
2022 The transcription factors Junb and Fosl2 cooperate to regulate Cdh3 expression in 15P-1 Sertoli cells. Molecular reproduction and development 8 36468795
2019 Hypotrichosis with cone-rod dystrophy in a patient with cadherin 3 (CDH3) mutation. Documenta ophthalmologica. Advances in ophthalmology 8 30710256
2019 Hypotrichosis with juvenile macular dystrophy: Combination of whole-genome sequencing and genome-wide homozygosity mapping identifies a large deletion in CDH3 initially undetected by whole-exome sequencing-A lesson from next-generation sequencing. Molecular genetics & genomic medicine 8 31560841
2018 Trans-suppression of host CDH3 and LOXL4 genes during Cryptosporidium parvum infection involves nuclear delivery of parasite Cdg7_FLc_1000 RNA. International journal for parasitology 8 29438669
2023 MicroRNA 133A Regulates Cell Proliferation, Cell Migration, and Apoptosis in Colorectal Cancer by Suppressing CDH3 Expression. Journal of Cancer 7 37151391
2016 mRNA expression of CDH3, IGF2BP3, and BIRC5 in biliary brush cytology specimens is a useful adjunctive tool of cytology for the diagnosis of malignant biliary stricture. Medicine 6 27399126
2024 CDH3 Is an Effective Serum Biomarker of Colorectal Cancer Distant Metastasis Patients. Journal of Cancer 5 39247592
2021 The first Japanese family of CDH3-related hypotrichosis with juvenile macular dystrophy. Molecular genetics & genomic medicine 4 33837674
2025 Synergistic potential of CDH3 in targeting CRC metastasis and enhancing immunotherapy. BMC cancer 3 40155851
2025 Oxidative Stress Regulates CDH3 Expression in Lung Cancer Cells via OGG1-Mediated SP1 Binding. Antioxidants (Basel, Switzerland) 3 40227353
2025 CDH3 promotes the progression of lung adenocarcinoma through driving epithelial-mesenchymal transition progress. Journal of translational medicine 3 40781712
2023 3D Chromatin Architecture Re-Wiring at the CDH3/CDH1 Loci Contributes to E-Cadherin to P-Cadherin Expression Switch in Gastric Cancer. Biology 3 37372088
2022 A Novel Pathogenic CDH3 Variant underlying Heredity Hypotrichosis Simplex detected by Whole-Exome Sequencing (WES)-A Case Report. Cold Spring Harbor molecular case studies 3 35962736
2018 5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. Cancer medicine 3 29356434
1996 [Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]. The Journal of toxicological sciences 3 9021668
2022 The first reported case of CDH3-related hypotrichosis with juvenile macular dystrophy from Jordan: a case report. Ophthalmic genetics 2 35038959
2020 Correlating Adaptive Optics Images to Clinical Findings in Juvenile Macular Dystrophy with Hypotrichosis in Siblings with Homozygous CDH3 Pathogenic Variation. Ophthalmic research 2 31927556
2025 The First Colombian Patient with CDH3-Related Hypotrichosis with Juvenile Macular Dystrophy. Skin appendage disorders 1 40330852
2025 CDH3-AS1 antisense RNA enhances P-cadherin translation and acts as a tumor suppressor in melanoma. Cell reports 1 41037395
2024 Hsa_circ_0023179 modulated the processes of proliferation, apoptosis, and EMT in non-small cell lung cancer cells via the miR-615-5p/CDH3 axis. Biomolecules & biomedicine 1 39159001
2024 A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer. mAbs 1 39654063
2026 Preclinical Study of CDH3-Targeted 89Zr/177Lu Theranostics in Triple-Negative Breast Cancer. Molecular pharmaceutics 0 41570246
2026 CDH3 Mutation in Saudi Arabia: A Case of Hypotrichosis With Juvenile Macular Dystrophy. Cureus 0 42109964
2025 USP8-mediated CDH3 drives the malignant progression of lung adenocarcinoma by regulating ferroptosis. Tissue & cell 0 40700945
2025 Dietary plant-to-animal protein ratio and risk of premature coronary artery disease (PCAD): Iran Premature Coronary Artery Disease (IPAD) study. BMC cardiovascular disorders 0 40783723
2025 CDH3 as a Novel Therapeutic Target in Basal-like Double-Negative Prostate Cancer. bioRxiv : the preprint server for biology 0 41332717
2024 CDH3-AS1 antisense RNA enhances P-cadherin translation and acts as a tumor suppressor in melanoma. bioRxiv : the preprint server for biology 0 39764055
2022 Hypotrichosis with Juvenile Macular Dystrophy in a Patient with Cadherin 3 (CDH3) Mutation. Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 0 35996915

Missed literature

Know a paper Affinage missed for CDH3? Flag it for the maintainers and the community.

No submissions yet.